Shandong Weigao Blood Purification Products Co., Ltd. (SHA:603014)

China · Delayed Price · Currency is CNY

29.48

+0.42 (1.45%)

At close: Oct 23, 2026

Market Cap	12.32B -23.6%
Revenue (ttm)	3.76B +0.5%
Net Income	491.82M +4.7%
EPS	1.19 -4.9%
Shares Out	417.75M
PE Ratio	24.84
Forward PE	24.70
Dividend	0.52 (1.76%)
Ex-Dividend Date	Sep 14, 2026

Volume	1,226,780
Open	28.97
Previous Close	29.06
Day's Range	28.60 - 29.50
52-Week Range	28.71 - 49.01
Beta	n/a
Analysts	Strong Buy
Price Target	44.25 (+50.1%)
Earnings Date	Oct 31, 2026

About SHA:603014

Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China. It offers dialyzers; dialysis machines; hemodialysis tubing, products, and machines; peritoneal dialysis products; dialysis supporting products, such as hemoperfusion devices, dialysis powder and liquid, puncture needles, and iodine caps for peritoneal dialysis. It also offers prefillable syringe drug delivery systems. The company was founded in 2004 and is based in Weihai, China. [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2004

Employees 3,734

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603014

Full Company Profile

Financial Performance

In 2025, SHA:603014's revenue was 3.77 billion, an increase of 4.57% compared to the previous year's 3.60 billion. Earnings were 482.30 million, an increase of 7.33%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 603014 stock is "Strong Buy." The 12-month stock price target is ¥44.25, which is an increase of 50.10% from the latest price.

Price Target

¥44.25

(50.10% upside)

Analyst Consensus: Strong Buy

Stock Forecasts